StreetInsider.com News Articles

Lexaria completes enrollment in semaglutide oral delivery study

Wed, 21 Oct 2026 09:26:28 -0400

Lexaria Bioscience Corp. (NASDAQ: LEXX) announced that its Human Pilot Study GLP-1-H26-7 has reached full enrollment and is continuing dosing on schedule, according to a press release from the company.

The study is evaluating two oral DehydraTECH-semaglutide compositions against Novo Nordisk's commercially available Wegovy tablets over a five-week period. The final study arm began dosing in early October, with completion expected in mid-November, to be followed by laboratory sample analysis and reporting.

The study is structured across three arms assessing safety, tolerability, and pharmacokinetic properties. It compares SNAC-inclusive DehydraTECH-semaglutide formulations in both tablet and capsule formats against Wegovy tablets, conducted under fasted

Lexaria completes enrollment in semaglutide oral delivery study

Wed, 21 Oct 2026 09:26:28 -0400

Lexaria's Human Study GLP-1-H26-7 Reaches Full Enrollment and Continues Dosing on Schedule

Wed, 21 Oct 2026 09:25:00 -0400

KELOWNA, BC / ACCESS Newswire / October 21, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, reports that full enrollment has been reached and dosing continues on schedule with Human Pilot Study #7 (GLP-1-H26-7) which is evaluating two oral DehydraTECH-semaglutide ("DHT-sema") compositions against Novo's® commercially available Wegovy® tablets, over a 5-week duration (the "Study").

The final Study arm was fully enrolled and began dosing, as scheduled, in early October. This final group is expected to complete their dosing in mid-November, to be followed by

Lexaria's Human Study GLP-1-H26-7 Reaches Full Enrollment and Continues Dosing on Schedule

Wed, 21 Oct 2026 09:25:00 -0400

The final Study arm was fully enrolled and began dosing, as scheduled, in early October. This final group is expected to complete their dosing in mid-November, to be followed by

Lexaria reports animal study results for drug delivery formulations

Thu, 15 Oct 2026 09:21:23 -0400

Lexaria Bioscience Corp. (NASDAQ: LEXX) released results from animal study GLP-1-A26-1, which evaluated formulation enhancements using its DehydraTECH-CBD (DHT-CBD) and DehydraTECH-semaglutide (DHT-SEMA) drug delivery compositions, according to a company statement.

The study used Sprague-Dawley rats across 11 arms to measure pharmacokinetic performance and brain drug concentrations. Blood samples were collected over an 8-to-24-hour post-dosing period.

In blood plasma results, the DHT-CBD (ALT1) formulation showed higher absorption than the reference formulation, recording a mean peak concentration (Cmax/D) of 9.30 ng/mL per mg/kg versus 8.65 for the reference. None of the alternative DHT-CBD formulations showed statistically significant differences from the reference arm at the

Lexaria reports animal study results for drug delivery formulations

Thu, 15 Oct 2026 09:21:23 -0400

The study used Sprague-Dawley rats across 11 arms to measure pharmacokinetic performance and brain drug concentrations. Blood samples were collected over an 8-to-24-hour post-dosing period.

Lexaria Announces Results from Animal Study GLP-1-A26-1

Thu, 15 Oct 2026 09:10:00 -0400

KELOWNA, BC / ACCESS Newswire / October 15, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is pleased to provide the following results from animal study GLP-1-A26-1 (the "Study") that evaluated a number of formulation enhancements using both DehydraTECH-CBD ("DHT-CBD") compositions and DehydraTECH-semaglutide ("DHT-SEMA") glucagon-like peptide-1 ("GLP-1") compositions to explore the potential for additional improved performance, as well as stake new intellectual property ("IP") claims.

Lexaria has already filed 3 new patent applications related to the formulations evaluated in this Study to protect this

Lexaria Announces Results from Animal Study GLP-1-A26-1

Thu, 15 Oct 2026 09:10:00 -0400

Lexaria has already filed 3 new patent applications related to the formulations evaluated in this Study to protect this

Form EFFECT Lexaria Bioscience Corp.

Wed, 14 Oct 2026 06:04:00 -0400

si-local-file:///var/storage/secattach/20261014/27183223.html

Form 424B3 Lexaria Bioscience Corp.

Tue, 13 Oct 2026 17:15:00 -0400

si-local-file:///var/storage/secattach/20261013/27181947.html

GLP-1 Weight-Loss/Diabetes Industries Continue Transition to Oral Medications

Tue, 06 Oct 2026 09:10:00 -0400

KELOWNA, BC / ACCESS Newswire / October 6, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is providing this strategic update.

Lexaria's DehydraTECH™ technology is currently being evaluated both by Lexaria and pharmaceutical industry partners for use within the rapidly growing GLP-1 receptor agonist and weight-loss/diabetes drug industries. Those industry segments were valued at $62.8 billion in 2025 and are estimated to grow to $73.4 billion in 2026 and to $254.2 billion by 2034. This growth far exceeds earlier forecasts

GLP-1 Weight-Loss/Diabetes Industries Continue Transition to Oral Medications

Tue, 06 Oct 2026 09:10:00 -0400

Form S-3 Lexaria Bioscience Corp.

Fri, 02 Oct 2026 06:05:00 -0400

si-local-file:///var/storage/secattach/20261002/27138556.html

Form D Lexaria Bioscience Corp.

Mon, 21 Sep 2026 06:00:00 -0400

si-local-file:///var/storage/secattach/20260921/27082440.html

Lexaria raises $7.9M, extends cash runway through 2027

Thu, 17 Sep 2026 09:11:16 -0400

Lexaria Bioscience Corp. (NASDAQ: LEXX) said it has received combined net proceeds of $7.9 million from an Australian tax refund and an institutional financing round priced at $12.92 per share, according to a company statement.

With 2.1 million shares currently issued and outstanding, the company said the new capital, combined with its pre-existing cash balance, represents approximately $4.60 per share in cash on hand.

CEO Rich Christopher said the company does not intend to pursue additional equity or debt financing in 2026, and that the capital extends the company's cash runway through 2027.

Christopher attributed recent stock price pressure to what he described

Lexaria Updates Financial Position

Thu, 17 Sep 2026 09:10:00 -0400

KELOWNA, BC / ACCESS Newswire / September 17, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is providing the following update.

Lexaria is in a strong cash position following both its recently announced Australian tax refund and recent institutional financing priced at US$12.92/share. The combined net proceeds from these two items totaled US$7.9 million. With only 2.1 million shares currently issued and outstanding, the US$7.9 million in fresh new capital plus our pre-existing cash balance represents approximately US$4.60/share in current

Lexaria Updates Financial Position

Thu, 17 Sep 2026 09:10:00 -0400

Lexaria Announces Closing of Exercise of Warrants for Approximately $5.9 Million in Gross Proceeds

Wed, 09 Sep 2026 16:15:00 -0400

KELOWNA, BC / ACCESS Newswire / September 9, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, today closed its previously announced exercise of certain outstanding warrants to purchase an aggregate of 453,969 shares of the Company's common stock originally issued by the Company on February 16, 2024, having an original exercise price of $32.78 per share, on October 16, 2024, having an original exercise price of $45.90 per share, on September 29, 2025, having an original exercise price of $20.55 per share and

Lexaria Announces Closing of Exercise of Warrants for Approximately $5.9 Million in Gross Proceeds

Wed, 09 Sep 2026 16:15:00 -0400

Lexaria Bioscience raises $5.9M through warrant exercise

Tue, 08 Sep 2026 08:02:32 -0400

Lexaria Bioscience Corp. (NASDAQ: LEXX)(NASDAQ: LEXXW) has entered into definitive agreements for the immediate exercise of certain outstanding warrants, expected to generate approximately $5.9 million in gross proceeds before placement agent fees and other expenses.

The transaction involves the exercise of warrants to purchase an aggregate of 453,969 shares of common stock at a reduced exercise price of $12.92 per share. The warrants were originally issued on four separate dates between February 2024 and December 2025, with original exercise prices ranging from $17.85 to $45.90 per share. The transaction is expected to close on or about September 9, 2026, subject to

Lexaria Bioscience raises $5.9M through warrant exercise

Tue, 08 Sep 2026 08:02:32 -0400

Lexaria Bioscience raises $5.9M through warrant exercise

Tue, 08 Sep 2026 08:02:32 -0400

Lexaria Bioscience raises $5.9M through warrant exercise

Tue, 08 Sep 2026 08:02:32 -0400

Lexaria Announces Exercise of Warrants for Approximately $5.9 Million in Gross Proceeds

Tue, 08 Sep 2026 08:00:00 -0400

KELOWNA, BC / ACCESS Newswire / September 8, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, today announced the entry into definitive agreements for the immediate exercise of certain outstanding warrants to purchase an aggregate of 453,969 shares of the Company's common stock originally issued by the Company on February 16, 2024, having an original exercise price of $32.78 per share, on October 16, 2024, having an original exercise price of $45.90 per share, on September 29, 2025, having an original exercise price

Lexaria Announces Exercise of Warrants for Approximately $5.9 Million in Gross Proceeds

Tue, 08 Sep 2026 08:00:00 -0400